STRS Ohio’s SAB Biotherapeutics SABS Stock Holding History

STRS Ohio’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.1K	Buy	+8,500	New	+$31.6K	﹤0.01%	2083

Other funds holding SABS

HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

New York State Common Retirement Fund

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

STRS Ohio's SABS Position: Q2 2026 in Review

STRS Ohio opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 8,500 shares worth $33.1K. The stake represents ﹤0.01% of the portfolio and ranks #2083 among its holdings.

11 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

STRS Ohio held 8,500 shares of SAB Biotherapeutics worth $33.1K as of Q2 2026.
SAB Biotherapeutics was a new STRS Ohio position in Q2 2026.
SAB Biotherapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #2083 holding.
11 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.